Date: 2014-07-21
Type of information: Company acquisition
Acquired company: Alergo Pharma (Argentina)
Acquiring company: Stallergènes (France)
Amount: undisclosed
Terms: Stallergènes, a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, has acquired the entire share capital of Alergo Pharma, an Argentinean allergen immunotherapy (AIT) company. The terms of the transaction are not disclosed.
Details: The acquisition aims to combine two complementary dedicated allergen immunotherapy companies, working together to provide a more comprehensive and broader range of diagnosis and treatment solutions to patients suffering from allergic respiratory diseases. This acquisition establishes Stallergenes among the top allergen immunotherapy pharmaceutical companies in Latin America further broadening the group\'s geographic presence across the region. Currently, Stallergenes operates in 20 countries and employs over 1,000 people. In 2013, the Company generated total revenues of €248 million.
Related: Allergic diseases Respiratory diseases
